Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
INBRX-106 plus pembrolizumab nearly doubled the confirmed objective response rate in first-line PD-L1-positive metastatic/recurrent HNSCC: 48.3% vs 26.5% for pembrolizumab alone in the randomized Phase 2 HexAgon study, with median PFS of 9.6 vs 4.9 months at the August 19, 2026 data cutoff. The HPV+ subgroup showed the deepest benefit, with an 80.0% response rate, a 30.0% complete response rate, and 90.0% of patients progression-free at six months versus 33.3%, 0%, and 33.0% for pembrolizumab alone.
Key figures
- Drug Name
- INBRX-106
- Phase Of Trial
- Phase 2
- Data cutoff
- August 19, 2026
- Study sites
- more than 80
- Corr control
- 26.5%
- Pfs6 control
- 42.8%
- Corr combination
- 48.3%
- Pfs6 combination
- 72.4%
- Evaluable patients
- 63
- Randomized patients
- 68
- Hpv plus corr control
- 33.3%
- Hpv plus pfs6 control
- 33.0%
- Hpv plus corr combination
- 80.0%
- Hpv plus pfs6 combination
- 90.0%
- Median pfs months control
- 4.9
- Planned expansion patients
- approximately 50 additional HPV+ OPSCC patients
- Hpv plus cr rate combination
- 30.0%
- Median pfs months combination
- 9.6
- Complete response rate control
- 0%
- Hpv plus median pfs combination
- not yet reached
- Complete response rate combination
- 13.8%
- Hpv plus median pfs months control
- 4.6
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.